5 articles in this category
Imagine a world where 90-year-olds have the biological age of 40. Clinical trials for senolytic drugs are clearing age-related diseases at rates no on...
Your company will pivot. Maybe not this quarter, but soon. And when it does, most frameworks — the ones you spent months building — will shatter. They...
Imagine you are builded a longevity setup — a stack of intervening, biomarkers, and protocols — but the clock is ticking. Your investors want a go/no-...
Planned obsolescence is not an accident—it's a concept choice incentivized by the faulty metrics. For decades, engineers have measured reliability usi...
You have a compound that extends mouse lifespan by 15%. Your cells look younger under the microscope. Investors are excited. But when you scale to hum...